[go: up one dir, main page]

WO2015068935A1 - Composition pharmaceutique pour la prévention ou le traitement de maladies allergiques, comprenant un extrait de pterocarpus indicus sauvage en tant qu'ingrédient actif - Google Patents

Composition pharmaceutique pour la prévention ou le traitement de maladies allergiques, comprenant un extrait de pterocarpus indicus sauvage en tant qu'ingrédient actif Download PDF

Info

Publication number
WO2015068935A1
WO2015068935A1 PCT/KR2014/007253 KR2014007253W WO2015068935A1 WO 2015068935 A1 WO2015068935 A1 WO 2015068935A1 KR 2014007253 W KR2014007253 W KR 2014007253W WO 2015068935 A1 WO2015068935 A1 WO 2015068935A1
Authority
WO
WIPO (PCT)
Prior art keywords
allergic
extract
prevention
improvement
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2014/007253
Other languages
English (en)
Korean (ko)
Inventor
김택중
차해심
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Yonsei University
Original Assignee
Industry Academic Cooperation Foundation of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Yonsei University filed Critical Industry Academic Cooperation Foundation of Yonsei University
Publication of WO2015068935A1 publication Critical patent/WO2015068935A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention relates to a pharmaceutical composition for preventing or treating allergic diseases containing Pterocarpus indicus Willd extract as an active ingredient, health functional foods for preventing or improving allergic diseases, external skin preparations and cosmetic compositions.
  • allergens also known as type 1 hypersensitivity reactions
  • allergens enter the body through the respiratory, digestive and skin
  • they bind to IgE antibodies attached to receptors (Fc ⁇ RI) on the surface of mast cells in tissues.
  • Fc ⁇ RI receptors
  • Degranulation of mast cells releases histamine and immediately triggers an early allergic reaction.
  • leukotriene and various cytokines are secreted from mast cells, causing late allergic reactions such as tissue damage and inflammatory reactions.
  • Allergic diseases include rhinitis, asthma, atopic dermatitis, allergic conjunctivitis, etc., but as the number of environmental pollution increases, there is no treatment that can completely eliminate the cause.
  • rosewood fragrance is dried wood of Pterocarpus indicus Willd, and it has the effect of small size, orthodoxy, hemostasis, chemostasis, wall odor, urine pain, headache, heartache, orojeong, rubella, golden bleeding It is widely used in various diseases such as.
  • the inventors of the present invention block the secretion of allergens from mast cells that cause discomfort or sometimes fatal various allergic diseases such as allergic skin diseases, atopic dermatitis, allergic rhinitis, allergic asthma, etc. Efforts have been made to secure a substance that can treat allergic diseases. As a result, Pterocarpus indicus Willd extract inhibits the secretion of allergens from mast cells at low concentrations and shows an excellent antiallergic effect in allergic animal models. The present invention was completed by confirming the point.
  • an object of the present invention is to provide a pharmaceutical composition for preventing or treating allergic diseases containing Pterocarpus indicus Willd extract as an active ingredient.
  • an object of the present invention is to provide a skin external preparation and a cosmetic composition for preventing or improving allergic diseases containing Pterocarpus indicus Willd extract.
  • the present invention also provides a dietary supplement for preventing or ameliorating allergic diseases containing Pterocarpus indicus Willd extract, specifically water with sweet potato, C 1-4 lower alcohol or a mixed solvent extract thereof. Solved.
  • the present invention also provides a skin external preparation and cosmetic composition for preventing or ameliorating allergic diseases containing Pterocarpus indicus Willd extract, specifically, rosewood water, C 1-4 lower alcohol or a mixed solvent extract thereof. The problem was solved.
  • the extract of Pterocarpus indicus Willd according to the present invention inhibits the secretion of allergens from mast cells at low concentrations and exhibits an excellent antiallergic effect in allergic animal models. Therefore, the algae extract according to the present invention, unlike the conventional therapeutic agent for the relief of symptoms, by inhibiting or blocking the secretion of allergens in mast cells can be fundamental treatment of allergic diseases. Along with this, the algae extract has no cytotoxicity, and has fewer side effects, so it can be used as a safe drug, health functional food, as well as skin external preparations and cosmetics.
  • Figure 1 shows the results of measuring the effect of inhibiting the secretion of allergens from mast cells when treated with sweet potato extract concentration.
  • Figure 2 is a photograph showing the anti-allergic effect of the algae extract in an allergic animal model.
  • Figure 3 is a graph showing the results of measuring the anti-allergic effect of the rosewood extract in an allergic animal model.
  • Figure 4 is a graph showing the results of measuring cytotoxicity in mast cells added with sweet almond extract.
  • Figure 5 shows the results of measuring the effect of the algae extract on IL-4 expression in IgE / Ag-sensitized mast cells.
  • Figures 6a, 6b, 6c and 6d shows the results of measuring the effect of the algae extract on phosphorylation of Erk, Akt, Syk and JNK in IgE / Ag-sensitized mast cells.
  • Figure 7a and 7b shows the skin sensory evaluation pictures (a) and results (b) of the dorsal epidermis of mice induced with allergic dermatitis, respectively, according to the treatment of the almond extract.
  • Figure 8 shows the results of a change measurement test of the scratching behavior of the dorsal epidermis of the mouse induced allergic dermatitis according to the treatment of the sweet potato extract.
  • Figure 9 shows the measurement results for the change in serum IgE according to the treatment of the sweet almond extract.
  • the present invention relates to a pharmaceutical composition for preventing or treating allergic diseases containing Pterocarpus indicus Willd extract as an active ingredient.
  • the present invention also relates to a dietary supplement for the prevention or improvement of allergic diseases containing extract of Pterocarpus indicus Willd.
  • the present invention also relates to an external preparation for skin for the prevention or improvement of allergic diseases containing Pterocarpus indicus Willd extract.
  • the present invention also relates to a cosmetic composition for preventing or ameliorating allergic diseases containing Pterocarpus indicus Willd extract.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of allergic diseases containing Pterocarpus indicus Willd extract as an active ingredient.
  • the sweet potato extract may be extracted with water, C 1-4 lower alcohol or a mixed solvent thereof, specifically, may be extracted with water.
  • the allergic disease is selected from the group consisting of allergic dermatitis, allergic rhinitis, allergic asthma, allergic otitis media, anaphylactic shock, allergic conjunctivitis and atopic dermatitis. It may be a disease, but is not limited thereto.
  • the allergic dermatitis may be psoriasis, connective allergic dermatitis, urticaria and the like.
  • the pharmaceutical composition may be formulated in a formulation selected from the group consisting of tablets, granules, pills, capsules, solutions, injections, ointments and powders, but is not limited thereto.
  • the present invention provides a dietary supplement for the prevention or improvement of allergic diseases containing extract of Pterocarpus indicus Willd.
  • the sweet almond extract contained in the health functional food may be extracted with water, C 1-4 lower alcohol or a mixed solvent thereof, and specifically may be extracted with water.
  • the allergic disease is selected from the group consisting of allergic dermatitis, allergic rhinitis, allergic asthma, allergic otitis media, anaphylactic shock, allergic conjunctivitis and atopic dermatitis. It may be a disease, but is not limited thereto.
  • the allergic dermatitis may be psoriasis, connective allergic dermatitis, urticaria and the like.
  • the health functional food may be formulated in a formulation selected from the group consisting of tablets, granules, pills, capsules, solutions and powders, but is not limited thereto.
  • the present invention provides a skin external preparation for preventing or ameliorating allergic diseases containing Pterocarpus indicus Willd extract.
  • the sweet potato extract may be extracted with water, C 1-4 lower alcohol or a mixed solvent thereof, specifically, may be extracted with water.
  • the allergic disease is selected from the group consisting of allergic dermatitis, allergic rhinitis, allergic asthma, allergic otitis media, anaphylactic shock, allergic conjunctivitis and atopic dermatitis. It may be a disease, but is not limited thereto.
  • the allergic dermatitis may be psoriasis, connective allergic dermatitis, urticaria and the like.
  • the skin external preparation may be formulated in a formulation selected from the group consisting of external preparations, external preparations, external preparations, ointments, creams, gels, warnings, dressings, patches, sprays and suppositories. It may be, but is not limited thereto.
  • the present invention provides a cosmetic composition for preventing or ameliorating allergic diseases containing extract of Pterocarpus indicus Willd.
  • the sweet potato extract may be extracted with water, C 1-4 lower alcohol or a mixed solvent thereof, specifically, may be extracted with water.
  • the allergic disease is selected from the group consisting of allergic dermatitis, allergic rhinitis, allergic asthma, allergic otitis media, anaphylactic shock, allergic conjunctivitis and atopic dermatitis. It may be a disease, but is not limited thereto.
  • the allergic dermatitis may be psoriasis, connective allergic dermatitis, urticaria and the like.
  • the cosmetic composition is a soap, cleansing foam, cleansing cream, cleansing water, bath, skin lotion, skin softener, skin toner, lotion, cream, essence, astringent, emulsion, gel, lipstick, spray, shampoo It may be prepared in any one or more formulations selected from the group consisting of, rinse, treatment, body cleanser, pack, massage agent, face powder, compact, foundation, two-way cake and makeup base, but is not limited thereto.
  • the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier.
  • the composition comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations.
  • diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. Mix is prepared.
  • lubricants such as magnesium stearate, talc and the like can also be used.
  • Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • treatment includes the cure of allergic disease as well as the partial cure, improvement and alleviation of allergic disease as a result of applying the pharmaceutical composition of the present invention to allergic disease.
  • prevention refers to applying the pharmaceutical composition of the present invention to allergic diseases to suppress or block the symptoms of allergic diseases, thereby preventing atopic dermatitis from occurring in advance.
  • improved is meant to include alleviation, prevention or treatment of symptoms.
  • active ingredient means a component that exhibits activity alone or in combination with a carrier (carrier) that is not active in itself.
  • composition of the present invention is administered in a pharmaceutically effective amount.
  • the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to an individual type and severity, age, sex, activity of the drug. , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of the drug, and other factors well known in the medical arts.
  • the sweet almond extract of the present invention may be administered in 0.0001 to 50 mg / kg, specifically 0.001 to 50 mg / kg, but is not limited thereto.
  • compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents that exhibit antiallergic effects, and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, and can be easily determined by those skilled in the art.
  • the term "individual” means any animal including a human who has already developed or can develop a disease that can be prevented or treated through anti-allergic activity and by administering to a subject a composition comprising an extract of the present invention. The disease can be effectively prevented and treated.
  • the route of administration of the composition may be administered via any general route as long as it can reach the desired tissue.
  • the composition of the present invention may be administered as desired, but is not limited to intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, intranasal administration, pulmonary administration, rectal administration.
  • the composition may also be administered by any device in which the active agent may migrate to the target cell.
  • the health functional food of the present invention includes the almond extract, but may include a suitable food supplement.
  • the term "food additive” means a component that can be added to food supplements, and can be used by those skilled in the art as appropriately added to prepare a health functional food of each formulation. Flavors, colorants and fillers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stables, including various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors Although the agent, preservatives, glycerin, alcohol, carbonation agent used in the carbonated beverage and the like are included, the examples of the food additive additive of the present invention is not limited.
  • the term "health functional food” refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functions for the human body.
  • a useful effect for health use such as nutrient control or physiological action on the structure and function of the human body, etc.
  • the health functional food according to the present invention can be prepared by methods commonly used in the art In the manufacture, the raw materials and ingredients commonly added in the art can be prepared.In addition, unlike general medicines, foods are used as raw materials, and there are no side effects that may occur when the medicine is taken for a long time. Excellent portability, the health functional food of the present invention can be taken as an adjuvant to enhance the anti-allergic effect.
  • the mixed amount of the active ingredient may be suitably determined depending on the purpose of use (prevention, health or therapeutic treatment).
  • the sweet potato extract of the present invention in the manufacture of food may be included in an amount of 0.001 to 5% by weight, or 0.001 to 3% by weight in the raw material composition.
  • 0.01 to 2 g, specifically 0.02 to 2 g, and more specifically 0.3 to 1 g may be added based on 100 mL.
  • the amount may be used below the above range.
  • Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and the like and include all of the health foods in the conventional sense.
  • the health food composition of the present invention may contain various flavors or natural carbohydrates and the like as additional ingredients, as in conventional food.
  • the above-mentioned natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol.
  • sweetening agent natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.
  • the proportion of the natural carbohydrate is generally about 0.1 to 10 g, specifically about 1 to 8 g, more specifically 5 to 6 g per 100 mL of the composition of the present invention.
  • the sweet potato extract of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, coloring and neutralizing agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protection Sex colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages and the like.
  • the rosewood of the present invention may contain a fruit flesh for the production of natural fruit juice and fruit juice drinks and vegetable drinks. These components can be used independently or in combination.
  • the ratio of the additive is not very important, but is generally selected in the range of 0.0001 to about 10 parts by weight per 100 parts by weight of the sweet potato extract of the present invention.
  • the present invention provides a cosmetic containing the sweet potato extract as an active ingredient for the purpose of preventing and improving allergic diseases.
  • the rosewood fragrance extract base cosmetics cosmetics, creams, essences, cleansing foam, cleansing water, packs, soap
  • body cosmetics body lotion, body oil, body gel, soap
  • color cosmetics foundation
  • hair cosmetics shampoo, rinse, hair conditioner, hair gel
  • the like can be used in combination with the content of about 0.05 to 10.0% by weight based on the dry weight of the cosmetic.
  • the dried wood grains of Pterocarpus indicus Willd were dried and pulverized. 1.0 L of distilled water was added to 100 g of the crushed sweet potato, followed by extraction for 2 to 3 hours in a hot water of 100 ⁇ 5 ° C. A cooler was installed to maintain the temperature and prevent loss to the steam, and the extract of the algae extract obtained above was filtered under reduced pressure and freeze-dried to be used as a sample of this experiment.
  • Rosewood extract has been shown to inhibit the secretion of allergens from mast cells. To ensure that RBL-2H3 cells were cultured in minimal medium supplemented with antibiotics and 10% bovine serum.
  • 200,000 cells per well were incubated with 400 ng / mL DNP-specific IgE in a 24-well incubator. The next day the cultured cells were washed with PIPES buffer (25 mM PIPES, pH 7.2, 119 mM NaCl, 5 mM KCl, 0.4 mM MgCl 2 , 1 mM CaCl 2 , 5.6 mM glucose and 0.1% BSA), and then the antigen was washed. Pre-incubate for 30 minutes before addition. After pre-culture, the antigen was added at a final concentration of 50 ng / mL to induce stimulation.
  • PIPES buffer 25 mM PIPES, pH 7.2, 119 mM NaCl, 5 mM KCl, 0.4 mM MgCl 2 , 1 mM CaCl 2 , 5.6 mM glucose and 0.1% BSA
  • the secretion of allergens was determined by the activity of hexosaminidase, a marker of degranulation secreted from the medium, from p-nitrophenylacetyl- ⁇ -D-glucosaminide. Determined by the amount of free p-nitrophenyl.
  • the alkalescent extract according to the present invention inhibits the secretion of allergens of mast cells RBL-2H3 in a concentration-dependent manner ( 1).
  • IgE 0.5 g of IgE was subcutaneously inoculated into one ear of an ICR mouse for 24 hours, followed by oral administration of the algae extract suspended in 3% arabic gum, and 1 hour later, 250 ⁇ l (1 mg) of the antigen solution.
  • Antigen + 5 mg Evans Blue / mL PBS solution was injected via the tail vein. 30 minutes after the injection, the ears of the mouse were removed, extracted with 500 ⁇ l of formamide solution at 63 ° C. for 24 hours, and the extracted Evans blue was measured for absorbance at 620 nm to confirm antiallergic effect.
  • the sweet potato extract of the present invention suppressed allergic reactions caused by antigens by concentration.
  • DPH diphenylhydramine
  • RBL-2H3 cells were seeded in 6-well plates at 8 ⁇ 10 5 cells / well and incubated overnight in medium containing 400 ng / mL anti-DNP-specific IgE. After washing twice, it was resuspended in PIPES buffer and activated for 1 hour with DNP-BSA (50 ng / mL) in the absence of the dandelion extract and in the presence of the dandelion extract. After incubation, the cells were washed twice with ice-cold PBS. Total RNA was isolated using TRI reaction solution (Sigma-Aldrich, St. Louis, MO), but followed protocol. The concentration of total RNA was measured using a spectrophotometer.
  • Real-time Polymerization of Synthesized cDNA in LightCycler 96 (Roche Korea, Seoul, Korea) Using Real-time PCR with asymmetrical cyanine dye SYBR GREEN I (Roche Korea, Seoul, Korea) Measured by enzyme chain reaction.
  • rat IL-4 sense 5'-ACCTTGCTGTCACCCTGTTC-3 ';
  • Denaturation, annealing, extension conditions and number of cycles are as follows: 1 minute at 94 ° C., 45 seconds at 50 ° C., 45 seconds at 72 ° C., 35 cycles.
  • IL-4 an inflammatory cytokine
  • IL-4 induces IgE production in B cells to promote na ⁇ ve T cells into Th2 cells.
  • IgE / Ag-induced expression of IL-4 mRNA was shown to be significantly inhibited, and the effect was concentration dependent.
  • RBL-2H3 cells were dispensed into 6-well plates at 8 ⁇ 10 5 cells / well and cultured overnight in medium containing 400 ng / mL anti-DNP-specific IgE to sensitize the cells.
  • the cells were pretreated with a rosewood extract for 30 minutes and the cells stimulated with antigen were washed twice with cold PBS, followed by lysis buffer (RIPA buffer; 2 mM EDTA, 137 mM NaCl, 20 mM Tris-HCl, pH 8.0), 1 mM sodium vanadate, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1% Triton X-100, 10% glycerol and protease inhibitory tablets).
  • lysis buffer (RIPA buffer; 2 mM EDTA, 137 mM NaCl, 20 mM Tris-HCl, pH 8.0)
  • 1 mM sodium vanadate 10 mM NaF, 1
  • the mixture was centrifuged at 12,000 rpm for 5 minutes, and the supernatant was mixed with 8x SDS buffer for 5 minutes at 100 ° C for protein denaturation.
  • the protein samples thus obtained were subjected to SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) at 100 V for 130 minutes using 10% or 12.5% poly acrylamide gel, and then PVDF for 40 minutes at 17V. (polyvinylidene difluoride) membrane (Immunoblot PVDF membrane, BIO-RAD) was transferred to.
  • skim milk 3% or 5% skim milk was made with TBS-T (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween-20) and blocked for 1 hour, followed by blocking with each specific antibody. The reaction was reacted at 4 ° C. overnight. After reacting with HRP (horseradish peroxidase) antibody for 2 hours, non-specifically remaining antibody was washed with TBS-T and removed, and the chemiluminescence detector LAS4000 was detected using an enhanced chemiluminescence (ECL) detection kit (Dojen, South Korea). It was measured in (GE healthcare).
  • ECL enhanced chemiluminescence
  • DNCB (2,4-dinitrochlorobenzene) was dissolved as 1 w / v% in a mixed solution of acetone and olive oil (mixed volume ratio 3: 1) to induce atopic dermatitis.
  • Primary immunization was applied by applying 300 ⁇ L to 2 cm 2 of the dorsal region of male ICR mice. After 3 days of primary immunization, 250 ⁇ L of 0.5% DNCB was applied to the dorsal area and secondary immunization was performed by treating the same concentration and the same amount every other day for about 10 days.
  • the sweet potato extract group was applied 200 ⁇ L to the dorsal area at a concentration of 10 mg / mL once every other day from the second DNCB administration.
  • the skin condition is graded as erythema, itching and dry skin, edema and hematoma, soreness, thyroiditis, no symptoms 0 points, symptom weakness 1 point, normal 2 points, severe 3 points for these 5 items
  • the total score was given a score between a minimum of 0 (no symptoms) and a maximum of 15 (all symptoms severe).
  • the score was gradually increased in the group induced with atopic dermatitis by applying DNCB to 12 or more points, but in the experimental group applied with the almond extract, it was confirmed that the level was significantly lowered than that of the normal group ( 7).
  • Scratch behavior verification experiments were conducted to measure the number of scraping behaviors caused by atopic dermatitis through video shooting at 24 hour intervals after the second challenge.
  • IgE levels were measured at 450 nm using an IgE enzyme-linked immunosorbent assay (ELISA) kit for mice. Compared to the normal group, the concentration of IgE was increased by three times in the group that induced allergic dermatitis by applying DNCB, but the IgE was decreased in the group administered with DNCB and rosewood extract. As a result, it was confirmed that the rosewood extract reduces the allergic reaction due to the rise of immunoglobulin (FIG. 9).
  • ELISA enzyme-linked immunosorbent assay
  • the powders are mixed and mixed, followed by filling into an airtight fabric to prepare a powder.
  • Tablets are prepared by mixing the above components according to a conventional method for preparing tablets and then compressing them.
  • the capsules are prepared by mixing the above components and filling the gelatin capsules according to a conventional capsule preparation method.
  • sweet potato extract After dissolving 330 mL of water and 175 g of NaOH to completely dissolve, 10 mg of sweet potato extract was added with a small addition for about 30 minutes. The mixture was dried in a shaded and airy place until dry.
  • the ingredients are used according to the conventional methods in the cosmetic manufacturing field for cleansing lotion.
  • the ingredients are used according to the conventional methods in the field of cosmetic preparation for skin preparation.
  • the ingredients are used according to the conventional methods in the cosmetic manufacturing field for the production of serum.
  • the ingredients are used according to the conventional methods in the manufacture of cosmetics for the manufacture of lotions.
  • the ingredients are used according to the conventional methods in the cosmetic preparation for cream making.
  • the ingredients are used according to the conventional methods in the manufacture of cosmetics for the manufacture of packs.
  • the ingredients are used according to the conventional methods in the cosmetic manufacturing field for the manufacture of massage creams.
  • the ingredients are used according to the conventional methods in the manufacture of cosmetics for the production of makeup bases.
  • the powder ingredients are prepared according to conventional methods in the field of cosmetic preparation for the production of powder facts using the above ingredients.
  • the ingredients are used according to the conventional methods in the cosmetic production for two-way cake production.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne : une composition pharmaceutique destinée à la prévention et/ou au traitement de maladies allergiques ; un aliment fonctionnel de santé pour la prévention ou l'amélioration de maladies allergiques ; un agent dermique externe ; et une composition cosmétique, comprenant un extrait de Pterocarpus indicus sauvage en tant qu'ingrédient actif. L'extrait de Pterocarpus indicus sauvage selon la présente invention inhibe, à une faible concentration, la sécrétion des mastocytes induisant les allergies, a un bon effet antiallergique sur un modèle animal allergique, et ne présente pas de cytotoxicité. Il peut ainsi être utilisé utilement en tant que composition pharmaceutique pour la prévention ou le traitement de maladies allergiques ; en tant qu'aliment fonctionnel de santé pour la prévention ou l'amélioration de maladies allergiques ; en tant qu'agent dermique externe ; et en tant que composition cosmétique.
PCT/KR2014/007253 2013-11-05 2014-08-06 Composition pharmaceutique pour la prévention ou le traitement de maladies allergiques, comprenant un extrait de pterocarpus indicus sauvage en tant qu'ingrédient actif Ceased WO2015068935A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020130133546A KR20150051710A (ko) 2013-11-05 2013-11-05 자단향 추출물을 유효성분으로 함유하는 알레르기성 질환 예방 또는 치료용 약학적 조성물
KR10-2013-0133546 2013-11-05

Publications (1)

Publication Number Publication Date
WO2015068935A1 true WO2015068935A1 (fr) 2015-05-14

Family

ID=53041674

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/007253 Ceased WO2015068935A1 (fr) 2013-11-05 2014-08-06 Composition pharmaceutique pour la prévention ou le traitement de maladies allergiques, comprenant un extrait de pterocarpus indicus sauvage en tant qu'ingrédient actif

Country Status (2)

Country Link
KR (1) KR20150051710A (fr)
WO (1) WO2015068935A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102030127B1 (ko) * 2019-01-10 2019-10-08 주식회사 보타닉센스 운데칸 또는 운데칸알을 유효성분으로 포함하는 항알러지, 아토피 피부염 개선, 또는 피부 재생용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040047929A1 (en) * 2000-12-19 2004-03-11 Ecarma Virgilio Verzosa Method to enhance the immune system and used for the prevention and treatment of asthma
KR100756550B1 (ko) * 2007-02-26 2007-09-07 연세대학교 산학협력단 자단향추출물을 포함하는 고지혈증 및 지방간의 예방 및치료용 조성물
JP2010006708A (ja) * 2008-06-24 2010-01-14 Shiseido Co Ltd 皮膚外用剤、美白剤、抗老化剤および抗酸化剤
KR20110046624A (ko) * 2009-10-29 2011-05-06 정산생명공학 주식회사 사향쥐에서 얻은 사향추출물과 생약추출물을 함유하는 노화방지 복합 한방조성물
KR20110105142A (ko) * 2010-03-18 2011-09-26 우석대학교 산학협력단 미백, 항균, 항산화 및 보습 효과를 나타내는 한방 화장료 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040047929A1 (en) * 2000-12-19 2004-03-11 Ecarma Virgilio Verzosa Method to enhance the immune system and used for the prevention and treatment of asthma
KR100756550B1 (ko) * 2007-02-26 2007-09-07 연세대학교 산학협력단 자단향추출물을 포함하는 고지혈증 및 지방간의 예방 및치료용 조성물
JP2010006708A (ja) * 2008-06-24 2010-01-14 Shiseido Co Ltd 皮膚外用剤、美白剤、抗老化剤および抗酸化剤
KR20110046624A (ko) * 2009-10-29 2011-05-06 정산생명공학 주식회사 사향쥐에서 얻은 사향추출물과 생약추출물을 함유하는 노화방지 복합 한방조성물
KR20110105142A (ko) * 2010-03-18 2011-09-26 우석대학교 산학협력단 미백, 항균, 항산화 및 보습 효과를 나타내는 한방 화장료 조성물

Also Published As

Publication number Publication date
KR20150051710A (ko) 2015-05-13

Similar Documents

Publication Publication Date Title
KR101397961B1 (ko) 복합 생약 추출물（ｇｓｔ）을 유효성분으로 함유하는 알러지성 또는 비알러지성 피부 질환의 예방 및 개선용 조성물 및 이의 용도
WO2011059292A2 (fr) Concentré ou extrait de pousse d'aloès officinal favorisant fortement la croissance des cellules cutanées et présentant des effets anti-allergiques et antioxydants supérieurs
WO2015030328A1 (fr) Compositions pour prévenir ou traiter des troubles cutanés allergiques, contenant les agents gpcr19 comme ingrédients actifs
WO2018117725A1 (fr) Composition pour prévenir la chute des cheveux et favoriser la pousse des cheveux, comprenant des produits animaux marins fermentés
WO2015005630A1 (fr) Composition capable d'inhiber la sécrétion de tslp et de soulager des maladies allergiques
WO2021080129A1 (fr) Composition pour renforcer la barrière cutanée et soulager la dermatite atopique, comprenant de l'hydrangénol ou de la phyllodulcine en tant que principe actif
WO2016186349A2 (fr) Composition, contenant un extrait de quisaqualis indica, pour la prévention ou le traitement de l'hyperplasie prostatique
WO2019027167A1 (fr) Composition anti-vieillissement ou de régénération de la peau comprenant de l'acide pipéronylique en tant que principe actif
WO2024123024A1 (fr) Composition contenant un extrait de centipeda minima pour la prévention et le traitement de l'inflammation et des maladies auto-immunes et son procédé de fabrication
WO2016117762A1 (fr) Composition contenant un extrait de groseille à maquereau ou du glutathion
WO2018044122A1 (fr) Composition comprenant un extrait d'un mélange médicinal de plantes médicinales, destinée au traitement de la dermatite atopique
WO2018111042A2 (fr) Composition cosmétique comprenant un extrait de plantes médicinales en tant qu'ingrédient actif
WO2020218720A1 (fr) Composition pour la prévention ou le traitement de troubles musculaires ou l'amélioration de la fonction musculaire, contenant un extrait de leonurus japonicus ou de la léonurine
WO2022260454A1 (fr) Composition pour le traitement de la dermatite atopique ou le renforcement de la barrière cutanée ou la prévention du vieillissement de la peau, comprenant un extrait de forsythia velutina nakai
WO2015068935A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies allergiques, comprenant un extrait de pterocarpus indicus sauvage en tant qu'ingrédient actif
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
WO2016122091A1 (fr) Composition pharmaceutique pour la prévention et le traitement de maladie allergique ou de dermatite de contact, comprenant un extrait de cymbidium comme principe actif
WO2024071736A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies allergiques, contenant des cellules mortes de streptococcus pyogenes ou une protéine spea
KR101115503B1 (ko) 진피 추출물을 유효성분으로 함유하는 과민성 피부 질환 예방 및 치료용 조성물
WO2014185610A1 (fr) Composition pour prévenir la perte de cheveux ou favoriser la pousse des cheveux du fait de son contenu en extrait de son comme principe actif
WO2014051296A1 (fr) Composition pharmaceutique, composition cosmétique et composition d'aliment fonctionnel contenant un extrait de smilax glabra qui est le rhizome de smilax china pour des maladies allergiques
WO2017142368A2 (fr) Composition permettant de prévenir et de traiter une maladie cutanée allergique ou inflammatoire
KR20150041968A (ko) 파에오닥틸룸 트리코르누툼(Phaeodactylum tricornutum)의 용매 분획물을 유효성분으로 포함하는 염증성 질환 예방용 또는 치료용 조성물
WO2023149785A1 (fr) Composition pour la prévention et le traitement d'un œdème inflammatoire, comprenant un extrait de lysimachia christinae hance comme principe actif
KR20130114058A (ko) 천식 또는 아토피의 치료 또는 예방용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14860403

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14860403

Country of ref document: EP

Kind code of ref document: A1